Magnetar Financial’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Magnetar Financial’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-435,715	Closed	-$57.5M	–	1239
2025 Q1	$57.5M	Buy	+435,715	New	+$54.3M	0.76%	16
2022 Q3	–	Sell	-5,223	Closed	-$298	–	1550
2022 Q2	$298	Buy	5,223 +1,125	+27%	+$63.8K	﹤0.01%	1237
2022 Q1	$251K	Buy	+4,098	New	+$213K	﹤0.01%	1025

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Magnetar Financial's ITCI Position: Q2 2025 in Review

Magnetar Financial sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 435,715 shares — an estimated $57.5M sold.

Magnetar Financial first reported a position in ITCI in Q1 2022 and held it in 3 quarters. The position peaked at $57.5M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Magnetar Financial reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Magnetar Financial sold 435,715 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $57.5M.
Magnetar Financial first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 3 quarters.
Magnetar Financial's Intra-Cellular Therapies Inc. position peaked at $57.5M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Magnetar Financial's 13F filing for Q2 2025, filed 12 Aug 2025.